First Trust Nasdaq Pharmaceuticals ETF
FTXH
4 hedge funds and large institutions have $628K invested in First Trust Nasdaq Pharmaceuticals ETF in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
19.18% less ownership
Funds ownership: 50.81% → 31.64% (-19%)
33% less capital invested
Capital invested by funds: $931K → $628K (-$303K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$25.3K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$3.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$387K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$10.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
1
Virtu KCG Holdings
New York
| $587K | -$387K | -19,889 | -40% |
|
|
2
UBS Group
Zurich,
Switzerland
| $26K | +$25.3K | +1,300 | New |
|
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $11K | -$10.7K | -551 | -50% |
|
|
IA
4
IFP Advisors
Tampa,
Florida
| $4K | +$3.9K | +200 | New |
|
FTXH Hedge Fund Activity: Q1 2017 in Review
4 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q1 2017, worth a combined $628K — down 33% from $931K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new FTXH positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $25.3K. The largest seller was Virtu KCG Holdings, cutting an estimated $387K.
- 4 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q1 2017, up from 3 in Q4 2016.
- Funds reported $628K of First Trust Nasdaq Pharmaceuticals ETF stock for Q1 2017, down 33% quarter-over-quarter.
- 2 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q1 2017 and 0 closed out, a net change of +2 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q1 2017 was UBS Group, an estimated $25.3K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q1 2017 was Virtu KCG Holdings, an estimated $387K sold.
Based on aggregated 13F filings for Q1 2017.